News U10

New gelatine devices that mimic the body’s activity in bone regeneration

The NanoBioCel Group, Coordinator of Unit 10 of NANBIOSIS has led the development of new scaffolds (such as burns, trauma or tumour extractions), to regenerate critical bone defects that, in addition to physical support, offers the opportunity to release growth factors temporarily replacing the bone matrix and aiding the regeneration of bone tissue.

In order to make the material biodegradable, and reduce the risk of rejection, “we use a collagen derivative, a gelatine that is produced by processing collagen, since it has been found to be less cytotoxic than collagen itself, but maintains the properties we were looking for”, explains Pello Sánchez, member of the NanoBioCel group. In addition, for the polymerization of gelatine proteins and scaffold cohesion, they used a molecule that is extracted from the fruit of gardenia, genipina, “because it has a lower toxicity to the cells.”

All the tests and processes carried out to know the properties, biocompatibility and possible cytotoxicity of the scaffolds have been satisfactory. Preclinical studies have been performed on animals with promising results, which are in the process of being published. The group is trying now to improve what has been achieved to date, such as introducing other elements such as calcium, or other growth factors, that improve regeneration.

The project is part of a new line of research promoted by Drs. Gorka Orive and José Luis Pedraz, whose research group NanoBioCel of the Laboratory of Pharmacy and Pharmaceutical Technology of the UPV / EHU and CIBER-BBN coordinates Unit 10 of NANBIOSIS, used in the research. They also have counted with the collaboration of UCA (Unit of Arthroscopic Surgery), and the work of the company AGRENVEC, which was the supplier of the growth factors.

Bibliographic referenc

Sánchez, J.L. Pedraz, G. Orive .. Biologically active and biomimetic dual gelatin scaffolds for tissue engineering. International Journal of Biological Macromolecules, 98: 486-494 (2017). DOI: 10.1016 / j.ijbiomac.2016.12.092.

• Read More

New treatments for degenerative diseases of the retina

The final meeting of the TERET project took place last March, an initiative within the RETOS public-private collaboration initiative of the Ministry of Economy, Industry and Competitiveness funded with almost € 1 million. The project has been carried out over the past three years to develop new treatments for degenerative diseases of the retina, focusing specifically on age-related macular degeneration (AMD), diabetic retinopathy ( RD) and retinitis pigmentosa.

Unit 10 of ICTS NANBIOSIS has participated in carrying out the pharmaceutical formulation of the active principles, including the synthesis, chemical physical characterization and stability of the formulations over time, evaluation of the silencing capacity and viability of the formulations used in cellulare crops, together with the CIBER-BBN groups led by José Luis Pedraz (University of the Basque Country), Ramon Eritja (IQAC-CSIC) and Eduardo Fernández (U. Miguel Hernández de Elche) and the biotechnology companies Sylentis , LeadArtis and Leitat.

Gene silencing solutions have been used as a basis for this project through the use of interfering RNA (siRNA) nd multivalent antibodies in Trimerbody format.

• Read More

3DBio-impression systems and bio-ink for the regeneration of cartilage and bone

The Nanobiocel Group, coordinator of Unit 10 of NANBIOSIS participate in a public-private collaborative project to reach clinical application in the regeneration of osteochondral lesions, which mainly affect the knee and ankle joints.

The new project is funded by the Challenges-Collaboration program of the Ministry of Economy, Industry and Competitiveness. It has a budget of 691,000 euros for 3 years and the participation of two Spanish companies (Bioibérica and REGEMAT3D), the Higher Council for Scientific Research (CSIC), the University of Granada, the Center for Biomedical Research in Network Bioengineering, Biomaterials and Nanomedicine (CIBER -BBN) and its ICTS NANBIOSIS.

The companies and research groups participating in this project will work in the manufacture of three-dimensional mesh pieces or scaffolding designed with 3D bio-printing systems. These pieces will be fed with cells that make it possible to generate tissues in vitro to regenerate lesions. The ultimate goal is the development of new bio-inks (in which meshes and cells are combined) that are implanted in bone and cartilage.

In addition, the high prevalence of joint injuries makes them very interesting as the first application of bio-printing, with a view to its use in clinical practice”, Explains Patricia Gálvez, director of the Advanced Therapies Unit of Bioibérica, the coordinating company of this project.

A worldwide pioneering project

The company REGEMAT3D has developed a system of devices for bio-pioneering worldwide. This system, intended for research groups in its initial version, allows bio-printing three-dimensional meshes loaded with various cell types (chondrocytes and mesenchymal stem cells) for the regeneration of cartilage. This type of fabric has a number of advantages compared to others because of its relative simplicity, and above all because it is not necessary that a previous cultivation has been carried out.

From the scientific point of view, there are several improvements to be made in the area of 3D bio-printing to make this technology so promising can be used in the clinic with guarantees of success. It is necessary to develop new biomaterials for meshes that mimic biological materials with similar mechanical and chemical properties. These biomaterials have to be printable and their parameters have to be controllable. It is also necessary to access a well characterized and reproducible source of cells to feed these pieces that can be obtained in large quantities to be able to repair wide areas of tissue.

For this task, they have joined forces REGEMAT3D, Bioibérica, the Nanobiocel Group of CIBER-BBN, coordinator of Unit 10 of NANBIOSIS, the research group CTS-205 of the Department of Pharmacy and Pharmaceutical Technology and the research group CTS-963 of Advanced Therapies: Differentiation, Regeneration and Cancer, both belonging to the University of Granada and the Biomaterials Group of the Polymer Science and Technology Institute of CSIC, also belonging to CIBER-BBN.

All these companies and research groups contribute with their know how in bio-printing to the development of pharmaceutical products for the treatment of joint injuries, cellular therapies and biomaterials, in a way that constitutes a multidisciplinary consortium with wide guarantees of success.

“Promover el desarrollo tecnológico, la innovación y la investigación de calidad”

• Read More

Nanomedicine in B·Debate Fighting Blindness by Unit 10 of NANBIOSIS

The recent published Newsletter of Institut of Màcula and the Barcelona Màcula Foundation: Research for Vision reported about the forum B·Debate Fighting Blindness. Future Challenges and Opportunities for Visual Restoration, September 6-7 , that gathered more than thirty experts in the different areas related with blindness.

The second Session, about Nanotechnology and Nanomedicine, was chaired by Jose Luis Pedraz, Scientific Director of Unit 10 of NANBIOSIS and Gustavo Puras Ochoa, researcher of the group Nanobiocel, which coordinates Unit 10 of NANBIOSIS gave a lecture “Non-viral gene delivery for the treatment of inherited retinal disorders” :

Many devastating blinding disorders that affect the retina in the developed world have a well-known genetic background. Despite gene therapy strategies have made major advances in recent years, many of the patients affected by inherited retinal diseases must live under impaired vision, even with the best medical treatment. Therefore, the development of effective gene carriers represents a major challenge for the scientific community. At present, viral and non-viral vectors are the most employed approaches to deliver genetic material to the retina. Although first promising clinical trials results with viral vectors offer reasonable hope to patients affected by some inherited diseases that cause irreversible blindness such as Retinitis Pigmentosa, Stargardt´s disease, Choroideremia and Age related Macular Degeneration, important concerns related to the risk of oncogenesis, immunogenicity, inflammatory responses, and the persistence of viral vectors in brain after intravitreal injection have garnered the interest to invest on non-viral gene transfer methods. Compared with their counterparts, non-viral vectors offer many important advantages, since are less limited by the size of the gene to transfect, do not raise major safety concerns, are easier and cheaper to produce, and are classified as drugs rather than as biologist by the regulatory authorities.

Nanomedicine in B·Debate Fighting Blindness by Unit 10 of NANBIOSIS

• Read More

Micro and nano capsules that will increase the effectiveness and precision of medicine.

José Luis Pedraz, Scientific Director of Unit 10 of NANBIOSIS and members of NANOBIOCEL group, which coordinates Unit 10 of NANBIOSIS, explain for the TEKNOPOLIS program of EiTB, the first communication group in the Basque Country, the development of micro and nanocapsules, gels and scaffolds to solve the problems of administration of new drugs.

The new active principles – says Pedraz – that have emerged in recent years from studies of genetic engineering, the production of recombinant proteins and others, have generated new molecules whose characteristics are very different from the conventional active ingredients of chemical synthesis and have raised a series of problems with their administration that do not solve the classic pharmaceutical formulas of the type of tablets, capsules or injectables, this is the reason why it is necessary to develop new systems of administration based on micro and nano technologies that can be administered in a correct and efficient way for patients. These devices can be used for transplantation and treatment of different diseases such as Parkinson, Alzheimer or Diabetes.

Nanbiosis U10 Micro and nano capsules that will increase the effectiveness and precision of medicine.

• Read More

“It is necessary to increase our relationship with European research groups” by José Luis Pedraz – U10 of NANBIOSIS

Last Sunday, November 27, the Newspaper of Álava published a special supplement with the title “ALAVA 2020”. It contained an article by José Luis Pedraz (Scientific Director of Unit 10 of NANBIOSIS)

According to Dr. Pedraz, group leader of the CIBER-BBN NANOBIOCEL group, in the next future, important challenges with new technologies will allow a considerable advance in the treatment of diseases of genetic origins. In this context, it is crucial to increase the number of international contacts in order to be able to access new infrastructures more competitively. The opening of new lines of research and the creation of new research infrastructure through consortiums such as CIBER-BBN or the Unique Scientific and Technologic Infrastructure (ICTS) NANBIOSIS generate an advantageous situation to attract new investments and create new companies. Pedraz continues explaining that we must increase our relations with European research groups in order to build consortia with which participate in for European research calls.

The NANOBIOCEL Group, coordinator of Unit 10 of NANBIOSIS, currently participates in two European consortiums (DRIVE Project) and (BERENICE Project) .

"It is necessary to increase our relationship with European research groups" by José Luis Pedraz - U10 of NANBIOSIS

• Read More

Midyear meeting in Vitoria of European project DRIVE

CIBER-BBN participates in the project through NanoBioCel group, led by professor José Luis Pedraz Muñoz, Scientific Director of Unit 10 of NANBIOSIS, working on the optimization of formulations to be included in a bioartificial organ.

José Luis Pedraz Munoz and Jesus Izco coordinator of NANBIOSIS have participated in the meeting held in Vitoria on 3 and 4 of October.

The DRIVE objective is to develop new biomaterials and devices surgical transplantation and improve islet survival producing pancreatic insulin for the treatment of diabetes. Diabetes Mellitus is a chronic disease characterized by high blood glucose levels and affects 422 million people in the world, according to 2014 World Health Organization (WHO).

DRIVE is a four-year European project funded by the Horizon 2020 program for research and innovation of the Union European and endowed with 8.9 million euros. It is being conducted by 14 European partners and coordinated by the Royal College of Surgeons Ireland (Royal College of Surgeons in Ireland). Seeks to develop a bioartificial pancreas that is inserted into the body through minimally invasive techniques. To do this, they are being carried out preclinical studies to integrate this system in the human body and assess its effectiveness in people. The system will contain islets Pancreatic to restore the natural control of blood sugar and eliminate the need for multiple daily injections of insulin, thus improving the quality of life of patients.

Midyear meeting in Vitoria of European project DRIVE

• Read More

Nanbiosis in the 2ª General Assambly of DRIVE project, Venice (16th-17th 2016)

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of DRIVE project, held in Venice, May 16th-17th 2016.

The second General Assembly of European project DRIVE “DIABETES-REVERSING-IMPLANTS FOR ENHANCED VIABILITY AND LONG TERM EFFICACY”, took place last 16 and 17 of May in San Servolo Island, Venice. Jesus Ciriza, from NanoBioCel group, presented the work scheduled for this first year and the results obtained.

The DRIVE, a 4-year project to be carried out by 14 European partners, among which is CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment of diabetes.

CIBER-BBN participates in the project thought Unit 10 of NANBIOSIS with the role of:

-Development of hydrogel formulations for β-Gel

-Developing unlimited future sources of insulin-producing β-cells

-Testing β-cell function in β-Gel using 3D in vitro tissue model.

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of DRIVE project, held in Venice, May 16th-17th 2016.

• Read More

Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids

Jose Luis Pedraz, Scientific Director of Unit 10 of NANBIOSIS Drug Formulation unit and Ramon Eritja Scientific Director of Unit U29 of NANBIOSIS Oligonucleotide Synthesis Platform (OSP) (CIBER-BBN) have participated in the entrapment of cationic nioplexes in supramolecular hydrogels and the use of these materials for transfecting cells.

This work is focused on entrapping cationic nioplexes within supramolecular hydrogels based on N-protected phenylalanine. To modulate the supramolecular hydrogel diffusion properties, hydrogels were easily tuned with ĸ-carrageenan (≤ 1%). These materials were fully characterized using rheology. The niosomal liberation in solution through hydrogels was monitored by fluorescence and this release was controlled by diffusion mechanisms. The lack of toxicity of these materials allowed these materials to be used in cell culture. Preliminary transfection results confirmed the suitability of entrapping niosomal formulations in supramolecular hydrogels and the potential opening up of alternative strategies in therapy.

This study was published in RSC Advances:

S. Grijalvo, G. Puras, J. Zárate, R. Pons, J.L. Pedraz, R. Eritja, D. Díaz. “Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids” 2016, 6, 39688-39699. DOI: 10.1039/C6RA01005A

Nanbiosis_U10_Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids

• Read More

José Luis Pedraz, Scientific Director of the Unit 10: Drug Formulation of NANBIOSIS explained DRIVE European project in the third edition of Diabetes Experience Day, diabetic patients meeting that gathered 1500 people in Madrid. The DRIVE project, in which participate fourteen partners from seven European countries, among which is the CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment diabetes.

The DRIVE project, in which participate fourteen partners from seven European countries, among which is the CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment diabetes.

NANBIOSIS participation in the project focuses on the evaluation of the biocompatibility of new biomaterials with insulin-producing cells. These new biomaterials provided by Contipro will be compared with the biomaterials most frequently used to encapsulate cells such as alginate derivatives, a product obtained from seaweed.

At the same time, the research group coordinating Unit 10 of NANBIOSIS work in differentiating IPC insulin producing cells as an alternative to pancreatic islets for use in bioartificial organ source, with the aim of addressing the problems of availability of pancreatic islets for such therapies.

DRIVE European project 3rd edition of Diabetes Experience Day.

Nanbiosis_Unit8-Drive Project-Improving transplant pancreatic cells_Dr. Jose Luis Pedraz

• Read More

You are here : Home / News U10 (Page 6)